Read Bio
Trish McClay is the OncoIntelligence Director at PreciseDx. She brings more than 30 years of oncology experience in the biotech, pharmaceutical, and diagnostic laboratory industries, with start-up ventures Centocor and Genomic Health, as well as established companies IDEC and RPR/Aventis Pharmaceuticals. Trish brings experience in both solid tumors and hematologic malignancies, in roles including sales, marketing, training, and medical education, with a strong background in the field of breast cancer. As a Product Manager, Trish launched Arcola Laboratories, RPR’s flagship generic division, and brought to market their first two products before transitioning into oncology where she launched Oncaspar®, RPR’s first oncology product for Acute Lymphoblastic Leukemia. She was also part of the original internal launch team that brought Taxotere® to market for breast cancer patients in the United States. Trish assumed sales roles at RPR/Aventis and IDEC, and was responsible for multiple products, including the promotional launches of Taxotere®, Anzemet®, Gliadel®, Rituxan®, and Zevalin®. In 2003, Trish was hired to the inaugural commercial launch team at Genomic Health, a pre-IPO start-up, to introduce the first-in-class Oncotype DX® breast cancer assay in the Northeast Region, which went on to become the standard of care for early-stage breast cancer patients. She went on to launch several additional first-in-class multi-gene assays, for Stage II Colon Cancer, DCIS, and Prostate Cancer, as well as a PAN-Cancer NGS test. Trish earned a Bachelor of Science in Business Administration from Thomas Edison State University in New Jersey. Most recently, she has provided consulting services for two start-up companies in the G.I. and breast oncology arena.
